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Strategies for antiviral stockpiling for future influenza pandemics: a 
global epidemic-economic perspective. 
Luis R. Carrasco, Vernon J. Lee, Mark I. Chen, David B. Matchar, James P. Thompson, Alex R. Cook 
 
Abstract 
Influenza pandemics present a global threat due to their potential mortality and substantial economic 
impacts. Stockpiling antiviral drugs to manage a pandemic is an effective strategy to offset their negative 
impacts; however, little is known about the long-term optimal size of the stockpile under uncertainty 
and the characteristics of different countries. 
Using an epidemic-economic model we studied the effect on total mortality and costs of antiviral 
stockpile sizes for Brazil, China, Guatemala, India, Indonesia, New Zealand, Singapore, the UK, the USA, 
and Zimbabwe. 
In the model, antivirals stockpiling considerably reduced mortality. There was greater potential 
avoidance of expected costs in the higher resourced countries (e.g. from $55bn to $27bn over a 30-year 
time horizon for the USA) and large avoidance of fatalities in those less resourced (e.g. from 11.4 to 2.3 
million in Indonesia). Under perfect allocation, higher resourced countries should aim to store antiviral 
stockpiles able to cover at least 15% of their population, rising to 25% with 30% misallocation, to 
minimise fatalities and economic costs.  
Stockpiling is estimated not to be cost-effective for two thirds of the world's population under current 
antivirals pricing. Lower prices and international cooperation are necessary to make the life-saving 
potential of antivirals cost-effective in resource-limited countries. 
 




Influenza pandemics have occurred over the past few centuries at intervals of between 10 and 40 years 
(Potter, 2001) causing high morbidity and mortality and enormous economic impacts. Many countries 
practiced stockpiling on antiviral drugs (henceforth, “antivirals”) such as oseltamivir (Tamiflu ®) and 
zanamivir (Relenza ®) before the emergence of influenza A (H1N1-2009) as an essential strategy for 
pandemic response before a new vaccine could be widely distributed (Hayden, 2001); however, we 
know little about the adequate long-term size of  stockpiles under uncertainty, vaccine availability and 
the characteristics of different countries, leading to the risk of misallocation of limited public health 
resources (Dhankhar et al., 2009). 
The effect of management strategies like prophylaxis and treatment with antivirals, vaccination and 
school closures has been studied using complex dynamic models (Ferguson et al., 2005, Ferguson et al., 
2006, Sander et al., 2009, Germann et al., 2006, Longini et al., 2004). However, such models have 
infrequently been used to evaluate the cost-effectiveness of management strategies. In addition, the 
computation time required for such complex models complicates the implementation of model 
optimization to obtain economically optimal management strategies that account for the stochasticity of 
the modelled systems. With a considerably lower spatial and temporal resolution, there are few very 
insightful studies on the assessment of the cost-effectiveness of antiviral stockpile use (Lugnér and 
Postma, 2009, Lee et al., 2006, Balicer et al., 2005, Siddiqui and Edmunds, 2008). These studies are 
normally non-dynamic or limit the scope to a single pandemic wave; with the economic impacts for 
longer time horizons estimated by weighting the obtained costs with the probability of a pandemic 
occurring. While useful, this approach presents some limitations: (i) it might not represent the 
distribution of potential pandemic combinations, e.g. several pandemics might occur in a short period of 
time and each pandemic can involve several waves; (ii) stochastic optimization is usually not performed, 
i.e. estimation of the most adequate stockpile size given the variability in the system; (iii) the 
development and availability of vaccines is usually not considered; and (iv) it is difficult to account for 
dynamic logistic problems (e.g. stockpile replenishment). Given the complexity of the epidemic and 
economic interactions of the system, interdisciplinary epidemic-economic dynamic models would be 
necessary to advance the state of knowledge on the economics of antivirals stockpiling (Lugnér et al., 




We considered the problem of estimating the antiviral stockpile size and the proportion of susceptible 
and infected individuals that should be managed by antiviral prophylaxis and treatment with the 
objective of minimising the expected value of: (i) the net present value of total costs; (ii) number of 
fatalities; (iii) and costs per quality-adjusted life year (QALY) given the uncertainty of the severity and 
frequency of future pandemics. A range of countries, spanning different sizes and stages of 
development, were considered—Brazil, China, Guatemala, India, Indonesia, New Zealand, Singapore, the 
UK, the USA, and Zimbabwe—thereby allowing a global perspective of the potential health and 





We adopted a simulation approach in which emergence and spread of pandemics over a time horizon 
occur at random and are modelled with a compartmental epidemic model. The results are then linked to 
an economic sub-model that quantifies the costs due to the pandemics. Given that the occurrence of 
future pandemics is very uncertain, our approach consists of repeating the same simulation experiment 
a large number of times (using Monte-Carlo simulation) to gain insights on the distribution of the 
potential outcomes. Furthermore, by embedding control by antivirals and vaccines into the epidemic 
model (Appendix A) we can evaluate the distributions of potential results for different levels of antiviral 
stockpile sizes. Comparing the evolution of the distributions of fatalities and total costs obtained in this 
way, we gain insight into adequate stockpile sizes for each country. 
The model 
Epidemic sub-model 
We developed a dynamic, hybrid deterministic-stochastic simulation model, with a time horizon of 30 
years and a time step of 1 day. We modelled the occurrence of a pandemic in the time horizon as a 
Poisson stochastic process.  Once a pandemic starts, we modelled it using a deterministic susceptible-
latent-infected-asymptomatic-recovered (SLIAR) model (Anderson and May, 1992, Diekmann and 
Heesterbeek, 2000 ) (see Appendix A for the mathematical description of the model). The SLIAR model 
divides the population into compartments that represent the number of individuals at each state in each 
time step. The effects of the antivirals used for prophylaxis and treatment, the proportions of individuals 
treated (Appendix A) and the population growth rates for each country (Table S1.2 in the electronic 
supplementary material, ESM 1) were incorporated in the model. 
The basic reproduction number, R0, is the average number of secondary cases from an infected 
individual in an otherwise susceptible population, and encapsulates the eventual magnitude of an 
epidemic (Anderson and May, 1992, Diekmann and Heesterbeek, 2000 , Roberts, 2007). We considered 
the R0 of each pandemic to be stochastic and to follow an assumptive uniform distribution between 1.4 
and 3.9, a range encompassing those of past observed pandemics in 1918–9, 1957–8, 1968–9 and 2009 
(Mills et al., 2004, Fraser et al., 2009). Keeping the infectious period fixed, we derived the transmission 
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probability from R0 (Appendix A). In this way the number, time of occurrence and conditions of each 
pandemic was stochastic, though once started, the epidemic itself was treated as deterministic. 
For countries in temperate regions, each pandemic can consist of several waves due to climatic 
seasonality (increased transmission rate in winter) or school terms and holidays. We modelled this 
seasonality through a yearly sinusoidal oscillation of the transmission rate (Ferguson et al., 2003). A 
cosine function where the magnitude of seasonal oscillation was parameterised for the H1N1 2009 
pandemic was utilized (Towers and Feng, 2009). No seasonality due to climate was assumed in tropical 
countries (Chow et al., 2006). 
We assumed that 6-8 months after the beginning of each pandemic an effective vaccine is developed, 
based upon the times of vaccine development and availability observed for the H1N1 2009 pandemic 
(Greenberg et al., 2009), although in the future this lead time might be shortened. 
Impacts 
The proportion of infected individuals leading to fatalities was modelled using a uniform distribution 
that encompassed the proportions observed in the 1918–9, 1957–8, 1968–9 (Siddiqui and Edmunds, 
2008) and 2009 pandemics in the UK. This distribution was used as a baseline distribution that was 
shifted to reflect different countries characteristics using estimates of the case fatality rate per country 
that was elicited from vital registration data from the 1918-19 pandemic for all countries (Murray et al., 
2006). Quality-adjusted life years (QALYs) lost due to death were calculated using the case fatality rates 
of the 1918–9, 1957–8, 1968–9 and 2009 pandemics and current life expectancy and population age 
distributions for each country considered (ESM 1). 
The direct economic impacts due to the pandemics were: costs of general practitioner consultation, 
treatment for complications and hospitalization costs (see ESM 1 for their estimation). 
The indirect economic impacts due to job absenteeism were calculated using the friction cost method 
(Koopmanschap et al., 1995) which is an alternative to the human capital method. All costs were 
expressed in 2009 US dollars. 
Control: stockpile dynamics 
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We consider that at the beginning of the time horizon, a full stockpile of oseltamivir is purchased, and 
throughout we assume that the policy is to maintain the stockpile at the chosen size, except as it is 
depleted mid-pandemic. The model tracks the ageing of the stockpile. If the shelf-life of the stockpile is 
reached without it being used, it is disposed of and replaced by a new stockpile of the same size. If a 
pandemic occurs, the stockpile is used for prophylaxis and treatment according to the proportions 
determined by the government until it is finished or until the end of the pandemic. To represent the 
postulated overwhelming demand of antivirals during a pandemic, the stockpile cannot be replenished 
until the pandemic is over. Once the pandemic is finished, the stockpile is replenished or replaced as 
appropriate (see ESM 1 for the estimation of the costs derived from stockpiling antivirals). 
Policy decision 
The government has to decide on (i) the size of the stockpile and (ii) the proportion of susceptible and 
infected individuals that receive antivirals for prophylaxis and treatment. We assume that the outbreak 
has gone undetected until 1% of the population of the focus country is infected, and that by this time 
importations of infection are similarly proportional to country size, reflecting more entry pathways in 
larger countries.  Following the experience of the 2009 pandemic, we disregard the possibility that the 
novel strain can be rapidly identified and eliminated. To evaluate the cost-effectiveness ratio of antiviral 
stockpiling, we compare the costs per QALY gained with a threshold of thrice the gross national income 
per capita of the country, following the advised cost effectiveness target of the World Health 
Organisation Commission on Macroeconomics and Health (Sachs, 2001). Model equations and 
parameters and the estimation of the economic impacts for each country are described in the Appendix 





Reduction of fatal casualties  
For all countries, greater stockpile sizes led to a reduction of expected mortality. This reduction, both in 
the mean and 95th percentile, presented sharply diminishing marginal returns, i.e. increasingly large 
stockpile sizes were needed to obtain the same reduction in mortality (figure 1a–c, and in the ESM 
figure S2.1 a–c and figure S3.2 a–d). For stockpile sizes greater than 15% of the total population the 
reduction of fatal casualties tended asymptotically to a constant level of expected number of fatalities 
that could not be reduced further using only antivirals. Stockpiling beyond this 15% target led to an 
expected inefficient surplus of antivirals that are not used. The minimum at stockpile sizes of 15% was 
consistent for both the mean and the 95th percentile, indicating that a relatively small stockpile was also 
protective for severe projections. If misallocation and misdiagnosis were both 30%, the new stockpile 
size, for which the asymptotic constant level of fatal casualties will occur, would be for stockpile sizes of 
25%, again, fairly constant across countries of different levels of economic development (ESM 2), 
although the expected level of mortality would be higher, especially in resource-limited countries (ESM 
2). 
Economically optimal stockpile size 
For small stockpile sizes, the costs due to job absenteeism and hospitalizations dominated until reaching 
a minimum at which  costs increased because of wastage of the growing unused stockpile, resulting in a 
J-shaped curve (figure 1 d–f; ESM 2, figure S2.1 d–f and figure S2.2 e–h). The optimal stockpile size to 
minimise the expected cost per QALY gained was very similar to the optimal size that minimised the net 
present value of the total costs and the point at which the number of fatal casualties as a function of 
stockpile size tended to an asymptotic level (figure 1 a–f, and ESM 2 figures S2.1 and S2.2). 
Using the cost-effectiveness criterion, we compare the costs per QALY gained with a threshold of thrice 
the gross national income per capita of the country (figure 1 g–i and ESM 2, figures S2.1 g–i and S2.2 i–l) 
(Sachs, 2001). According to this criterion, stockpiling was clearly cost-effective for the higher resourced 
countries like the USA, the UK, New Zealand and Singapore (figure 2). Under the lower pricing scheme 
for resource-limited countries (Mengewein, 2009), stockpiling was cost-effective for Brazil and only 
marginally so for China; it was however non cost-effective for Guatemala, India, Indonesia and 
Zimbabwe (figure 1 g, h, i and ESM 2 figure S2.1 g, h, i and S2.2 i, j, k and l). 
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Since antiviral stockpiling is not cost-effective for Guatemala at current prices, it seems reasonable to 
assume that for countries with lower per capita Gross National Income than Guatemala antiviral 
stockpiling will be non cost-effective.  In this case, around 46% of the world population live in countries 
where antiviral stockpiling is not cost-effective. Including China in this group (since stockpiling there is 
only marginally cost-effective) causes this figure to rise to around 66%, at current cost trends. Were 
generic antivirals not protected by a patent and available at a price below $2 per course, purchasing 
costs would drop to the level at which stockpiling would become cost-effective for China, Indonesia and 
India (figure 2), though it would still be cost-ineffective in Zimbabwe, and by extension, least resource-
limited countries.  
Proportion of antivirals for prophylaxis and treatment and vaccines availability 
Both the minimum expected number of fatalities and the minimum level of total costs occurred 
consistently when the antiviral stockpile was used exclusively for treatment and not for untargeted 
prophylaxis (See ESM 2, figure S2.3 and S2.4). Antivirals used for prophylaxis had a very limited 
mitigating effect on the pandemic but had a high opportunity cost, i.e. stocks that are useful for 
treatment are better used for this purpose than prophylaxis, and once sufficient stocks for treatment 
are reached, increasing the stock for prophylaxis use led to costs outweighing benefits.  
A mean delay in vaccine availability for subsequent waves of the pandemics from 240 to 350 days did 
not have a noticeable effect on the total number of fatalities (See ESM 2, compare S2.5. S2.6, S2.7 with 
S2.12, S2.13 and S2.14). This result represents a lower bound of vaccine effectiveness since we did not 
consider in the model waning of immunity in recovered individuals and the antigenic drift in the 




The results demonstrated that stockpiles—covering 15% of the population for perfect allocation and 
25% for 30% misallocation—attain considerable reductions of both mortality and total costs in all 
countries we considered, suggesting that the pattern holds for countries with varied sizes, influenza 
seasonality, and stages of economic development. 
The results also showed that, for all the countries considered, it was preferable not to use antivirals for 
prophylaxis of susceptible individuals but to reserve them for treatment of infected individuals, since, if 
antivirals are scarce, their use for prophylaxis implies a large opportunity cost because they could be 
more effectively deployed as treatment for infected individuals. To some extent, this result can be 
attributed to the epidemic model used, as the assumption of homogeneous mixing prohibits targeted 
prophylaxis, which may be feasible via contact-tracing at an early stage of the outbreak (Longini et al., 
2004, Ferguson et al., 2006, Germann et al., 2006) and has been demonstrated to be effective in semi-
closed populations such as army camps (Lee et al., 2010). However, on the whole, our results have clear 
implications; especially in the case of advanced epidemics where contacts with exposed individuals 
cannot be fully traced back, the use of antivirals for prophylaxis for the general public would represent 
an inefficient allocation of valuable resources and paradoxically lead to an increase of the number of 
fatalities if an efficient stockpile size had been put in place.  
The administration of antivirals is not always achievable within one day of symptom onset and not all 
influenza-like-illness cases are due to the pandemic strain leading to some potential misallocation of 
antivirals. The proportion of misallocation of antivirals will depend on the country’s health and antiviral 
distribution systems. Apportionment for greater stockpile sizes (increase from 15% to 25%) will partially 
compensate for misallocations and misdiagnosis; however this does not prevent all of the resulting 
increase in mortality. 
This study presents some limitations and could be extended in several ways.  Firstly, we decided not to 
incorporate the possibility of emergence of antiviral-resistant strains because, although they have been 
observed to emerge in patients treated with oseltamivir (Jackson et al., 2000), the fitness costs of 
resistance involved a reduction in infectiousness of the resistant strains such that they may not be 
capable of outcompeting wild strains (Ferguson et al., 2003). Secondly, the analysis was based on a 
generalisation from a sample of the three observed historical pandemics in the 20th century and one 
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from the 21st. The approach we took was to treat the severe 1918–9 pandemic as an upper bound for 
pandemic severity, but it is very possible that pandemics having characteristics beyond the observed 
range might occur, black-swan-style i.e failure of past data to provide sufficient information for 
adequate future predictions (Taleb 2007, Lund 2007), so that the sample distribution of their 
characteristics underestimates the uncertainty in the true distribution.  Thirdly, certain population age 
groups or medical conditions present higher risk to pandemic influenza.  Due to the large scale of the 
study and because case fatality rates per age group vary for each pandemic, we preferred to model all 
the susceptible individuals as homogeneous. In reality, as the pandemic unfolds, high risk groups can be 
identified (e.g. elderly in the 1968-9 pandemic) and antivirals can be preferentially allocated accordingly, 
leading to a higher number of avoided fatalities per antiviral course used. By contrast, because we are 
treating all the individuals as homogeneous, we are implicitly assuming that information on high risk 
groups is not available. Therefore, our results of optimal antiviral stockpile sizes are conservative 
estimates since smaller stockpile sizes would attain the same number of fatalities reductions if the high 
risk age groups could be identified. 
A global international comparison of antiviral stockpiling cost-effectiveness demands the challenging 
consideration of the epidemic and socioeconomic heterogeneities between resourced and less-
resourced countries. Due to limitations in health systems resources, less-resourced countries are more 
vulnerable to pandemics and present higher mortality rates (Murray et al., 2006). Despite the high 
number of potential fatalities that could be avoided, stockpiling antivirals in resource-limited countries 
implies that valuable resources are not allocated to ongoing severe health problems like measles, 
malaria, or acquired immunodeficiency syndrome. The differences in the priorities between countries 
need to be reflected by using different discount rates which, in turn, can be surrounded by intense 
debate (Nordhaus, 2007). Whereas resource-limited countries risk higher mortality rates, resourced 
countries have a higher stake on economic losses derived from future pandemics. For instance, 
resourced countries have a more highly specialised labour which is more difficult to replace during a 
pandemic leading to very high productivity losses. 
Given the high connectedness of today’s world by international air travel, the interventions most likely 
to be effective at delaying the spread of a pandemic are those based on local control with antivirals 
(Cooper et al., 2006, Lee et al., 2010). Hence, it makes economic and ethical sense, both from a global 
perspective and from the perspective of resourced countries, for resourced-limited countries to be able 
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to have antiviral stockpiles. We estimated, however, that two thirds of the world's population live in 
countries where antiviral stockpiling is not cost-effective. The use of generic antivirals could make 
stockpiling cost-effective for China, Indonesia and India, enabling large stockpiles to be developed at low 
cost. Antivirals would still not be cost-effective for countries like Zimbabwe, highlighting the need for 
international cooperation. This is a particularly relevant finding given that both Tamiflu® and Relenza® 
go off-patent in the next six years (2016 and 2013, respectively), especially since lower antiviral prices 
are necessary to make their life-saving potential cost-effective in the most resource-limited countries. 
We conclude that generic antivirals, international cooperation and a global network of national antiviral 
stockpiles will provide for a very high avoidance of economic impacts and fatalities due to future 
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A.1. Epidemic model 
We considered the compartments susceptible (S); latent (E); infectious asymptotic (A); infectious 
symptomatic (I); recovered (R); and dead (D). The parameters of the model are: the transmission 
probability between infectious symptomatic (ρ) and infectious asymptomatic (ρA) and susceptible; the 
population size (N); the proportion of infectious symptomatic individuals treated with antivirals (θtre); 
the proportion of susceptible individuals administered antivirals for prophylaxis (θpro); the latent period 
(µ); the proportion of latent individuals becoming asymptomatic (θasym);  the infectious period of 
infectious symptomatic (ε) and asymptomatic (εA) individuals; the rate of fatal casualties due to the flu 
(α); d1, d2, d3 and d4 are the effectiveness of the antivirals in reducing the infectious period, the death 
rate, the transmission rate from infectious non-treated to susceptible treated and from infectious 
treated to susceptible with no prophylaxis respectively. The model is expressed by a set of differential 
equations: 
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 (S 1.1) 
The expressions (S 1.1) indicates how the number of susceptibles decreases over time due to contacts 
between susceptible individuals not undergoing prophylaxis with untreated infectious symptomatic 
individuals (first element of Ω) and infectious symptomatic individuals treated with antivirals (second 
element of Ω); the contact between susceptible individuals undergoing prophylaxis with untreated 
symptomatic infectious individuals (third element of Ω) and treated symptomatic infectious individuals 
(fourth element of Ω); and the contact between susceptible individuals not undergoing prophylaxis (fifth 
element of Ω) and undergoing prophylaxis (sixth element of Ω) with infectious asymptomatic individuals. 




                       (S 1.2) 
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The expression (S 1.2) reflects how the number of latent individuals (non infectious) increases as a result 
of the contacts described above (Ω) and decreases because of latent individuals reaching the end of the 
incubation period and becoming either symptomatic infectious (third term in S 1.2) or asymptomatic 
infectious (fourth term in S 1.2). 
1 1t




            (S 1.3) 
The dynamics of the number of infectious asymptomatic (S 1.3) depends of the latent individuals 
becoming new infectious asymptomatic (second element in S 1.3) and the reduction of asymptomatic 
individuals as they reach the end of their infectious period (third element in S 1.3). 
         11 1 1 1 21 1 1 1 1t asym t tre t tre t tre t tre t
dI
E I d I I d I
dt
         
             (1.4) 
The dynamics of the number of infectious symptomatic individuals described by equation (S 1.4) 
depends on the number of latent individuals that become infectious symptomatic (second term in S 1.4) 
and the proportions of infectious that get recovered. Recovery rates will vary depending on the 
proportion of individuals untreated with antivirals (third element in S 1.4) and treated with antivirals 
(fourth element in S 1.4). A proportion of infectious symptomatic individuals die with two different 
rates: the first corresponding to infectious individuals untreated (fifth element in S 1.4) and treated with 
antivirals (sixth element in S 1.4). 
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Expression (S 1.5) describes the increase of individuals recovered from infectious symptomatic 
untreated (second element in S 1.5) and treated with antivirals (third element in S 1.5) and infectious 
asymptomatic individuals (fourth element in S 1.5). 
   21 1
t
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The magnitude of the pandemic was determined stochastically by sampling the basic reproduction 
number (R0) from a uniform distribution that encompassed the observed R0 in the pandemics of the 20
th 
century and the 2009 H1N1 pandemic. The transmission rate was obtained as a function of R0. The 
expression of R0 was obtained from the positive real eigenvalue of the next generation matrix 
(Diekmann and Heesterbeek, 2000 ) for the case of the continuous SLIAR model without control 
measures: 
   0 1 asym A A asymR

     

 
    
         
(S 1.7) 
Where κ = 0 is the relative infectiousness of latent with respect to symptomatic infectious individuals 
and ρA = 2ρ (Ferguson et al., 2003a). 
After a period of time T a vaccine of effectiveness γ against the pandemic strain is assumed to become 
available. A proportion (pvac) of the susceptible individuals is inoculated. The inoculated individuals are 
transferred to the recovered state after the vaccination according to: 
     1 vacS T p S T    





Figure 1. The effect of antivirals stockpile size on the expected number of fatalities, the net present 




Figure 2. Cost-effectiveness of antivirals stockpiling as a function of the price of the antiviral course. 
Cost-effectiveness in the ordinate axis is represented as the quotient of thrice the gross national income 
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